FBR Upgrades Keryx Biopharma To Outperform, Sees Meaningful Auryxia Sales & Potential Label Expansion

By: via Benzinga
FBR’s Christopher S. James upgraded the rating for Keryx Biopharmaceuticals (NASDAQ: KERX) from Market Perform to Outperform, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.